top
Please input keywords
포스터 다운로드
World ADC San Diego2022丨YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy
The strategy of targeting EGFR and MET can potentially overcome resistance of EGFR-TKI and improve patient outcomes. YH013 is a fully-human EGFR x MET bispecific ADC developed using proprietary RenLite® platform with common light chain and knobs-into-holes technology. YH013 showed greater internalization activity, robust anti-tumor efficacy in NSCLC and PDAC PDX models co-expressing EGFR and MET, and outperformed benchmark antibodies at a lower dose (3 mg/kg). These results suggest that by optimizing specificity and improving safety profiles of EGFR-targeting ADCs, YH013 can be an effective subsequent treatment option for MET-driven EGFR-TKI resistant NSCLCs.
*Name
*Email
*Telephone
*Company
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*City